Abstract
Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neutralizing / administration & dosage
-
Antibodies, Neutralizing / adverse effects
-
Antibodies, Neutralizing / pharmacology
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / pharmacology*
-
Female
-
Humans
-
Infant
-
Male
-
Placebos / administration & dosage
-
Respiratory Syncytial Virus Infections / drug therapy*
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus, Human / drug effects*
-
Respiratory Syncytial Virus, Human / immunology
-
Respiratory System / virology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neutralizing
-
Antiviral Agents
-
Placebos
-
motavizumab